Prolight Diagnostics shows proof of performance in whole blood

Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has demonstrated that its single molecule detection system gives equivalent performance in whole blood compared to plasma, without having to separate the cells from the sample.

“This is a very important breakthrough for our single molecule counting technology. We are not aware of any other single molecule counting platform that can function with whole blood. The ability to measure in whole blood, without a cell-separation step, reduces complexity, paving the way for an extremely competitive price level”, said Ulf Bladin, CEO of Prolight.

Prolight’s point-of-care troponin assay is developed to facilitate more rapid rule-in and rule-out of myocardial infarction (MI). The company has now demonstrated the ability to quantitatively measure in the single digit nanogram per litre range in whole blood. Fresh human blood samples were spiked using pooled plasma from patients with known elevated troponin levels post-MI. The troponin concentrations in the blood samples were confirmed by measuring them in parallel on a commercially available high-sensitivity troponin assay.